Summary
Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutical ingredients (APIs) and infant formulas. The company’s major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drug, supermarket and mass merchandise chains and direct sales representatives. The company has operations in North America, Europe, Australia and other countries including Israel and China. Perrigo is headquartered in Dublin, Ireland.
Perrigo Company Plc (PRGO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19
Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19
Perrigo Acquires ScarAway Brand from Enaltus 20
Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21
Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22
Perrigo to Acquire Women’s Healthcare Business from Lumara Health for USD82 Million 23
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 25
Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To US$129 Million 25
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 26
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 28
Venture Financing 30
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 31
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 33
Partnerships 34
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 34
Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 35
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38
Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40
Impax Labs Enters Into Co-Development Agreement With Perrigo 41
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 42
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 45
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46
Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 46
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 47
Licensing Agreements 48
TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 48
Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49
Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 49
Perrigo Enters into Licensing Agreement with Highland Pharma 51
Perrigo Enters into Licensing Agreement with Flamel Ireland 51
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52
Perrigo Enters into Licensing Agreement with Imago Pharma 53
Zogenix Amends Agreement with Elan Pharma 54
Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 55
Equity Offering 56
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56
Perrigo Raises USD1.03 Billion in Public Offering of Shares 57
Omega Pharma Completes Public Offering Of Shares For US$237 Million 59
Debt Offering 60
Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 60
Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 61
Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62
Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64
Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 65
Perrigo Completes Private Placement Of Notes Due 2023 For US$800 Million 67
Perrigo Completes Private Placement Of Notes Due 2043 For US$400 Million 67
Perrigo Completes Private Placement Of Notes Due 2018 For US$600 Million 68
Perrigo Completes Private Placement Of Notes Due 2016 For US$500 Million 69
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 70
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 71
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 72
Perrigo Completes Private Placement Of Notes Due 2023 For US$175 Million 73
Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For US$75 Million 74
Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For US$100 Million 74
Asset Transactions 75
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 75
Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 76
IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 77
Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 78
Watson Pharma Acquires Generic Pharma Products From Perrigo 79
Acquisition 80
Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 80
Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 81
Perrigo Acquires Omega Pharma for USD4.76 Billion 82
Ind-Swift Lab May Sell Stake in Company 83
Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 84
Perrigo To Acquire 7% Stake In Transition Therapeutics For US$15 Million 85
Perrigo Completes Acquisition Of Elan For US$8.6 Billion 86
Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For US$284 Million 88
Omega Pharma Acquires Naturoteek 90
Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For US$45 Million 90
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 91
Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For US$36 Million 92
Perrigo Completes Acquisition Of Paddock Labs 93
Perrigo Company Plc - Key Competitors 96
Key Employees 97
Locations And Subsidiaries 98
Head Office 98
Other Locations & Subsidiaries 98
Recent Developments 105
Strategy And Business Planning 105
Jan 11, 2016: Perrigo Company Increases 2016 Full-Year Adjusted Earnings Per Share Guidance 105
Financial Announcements 106
May 30, 2017: Perrigo Company Files First Quarter 2017 Form 10-Q And Reports First Quarter 2017 Financial Results 106
May 22, 2017: Perrigo Reports Fourth Quarter 108
Apr 25, 2017: Perrigo Announces Select Preliminary Unaudited First Quarter 2017 Financial Results 111
Feb 27, 2017: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance 112
Nov 10, 2016: Perrigo Company Reports Third Quarter 2016 Financial Results 114
Aug 10, 2016: Perrigo Company Reports Second Quarter 2016 Financial Results 117
May 16, 2016: Perrigo Company Reports First Quarter 2016 Financial Results 119
Feb 18, 2016: Perrigo Company Reports Record Fourth Quarter & Calendar Year Net Sales And Adjusted Net Income 121
Corporate Communications 123
Jun 05, 2017: Perrigo Announces Forthcoming Retirement Of CEO John Hendrickson 123
May 08, 2017: Perrigo Announces Two New Independent Directors 124
Feb 27, 2017: Perrigo Announces Leadership Changes 125
Nov 10, 2016: Perrigo Company Announces Appointment of Two New Independent Directors to Board 126
Apr 25, 2016: Perrigo Appoints John T. Hendrickson as Chief Executive Officer, Provides Preliminary First Quarter 2016 Selected Financial Results, and Updates Full Year 2016 Guidance 127
Feb 19, 2016: Perrigo Furthers Commitment to Ireland 129
Product News 130
Jun 19, 2017: Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution 130
Apr 12, 2016: Perrigo Announces First-to-Market Launch of the OTC Store Brand Equivalent to Glucerna Aseptic Adult Nutritional Shake 131
Mar 08, 2017: Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine Foam 132
Feb 17, 2017: Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution 133
Other Significant Developments 134
Jan 10, 2017: Perrigo Updates Segment Reporting Structure 134
Dec 08, 2016: Perrigo Announces Portfolio Review Developments And Intention To Restructure Branded Consumer Healthcare's Belgium Business 135
Appendix 136
Methodology 136
About GlobalData 136
Contact Us 136
Disclaimer 136
List of Tables
Perrigo Company Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Perrigo Company Plc, Deals By Therapy Area, 2011 to YTD 2017 11
Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19
Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19
Perrigo Acquires ScarAway Brand from Enaltus 20
Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21
Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22
Perrigo to Acquire Women’s Healthcare Business from Lumara Health for USD82 Million 23
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 25
Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To US$129 Million 25
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 26
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 28
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30
Proteostasis Therapeutics Raises USD22 Million in Venture Financing 31
Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32
Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 33
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 34
Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 35
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36
Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37
Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38
Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40
Impax Labs Enters Into Co-Development Agreement With Perrigo 41
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 42
Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43
Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 45
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46
Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 46
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 47
TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 48
Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49
Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 49
Perrigo Enters into Licensing Agreement with Highland Pharma 51
Perrigo Enters into Licensing Agreement with Flamel Ireland 51
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52
Perrigo Enters into Licensing Agreement with Imago Pharma 53
Zogenix Amends Agreement with Elan Pharma 54
Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 55
Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56
Perrigo Raises USD1.03 Billion in Public Offering of Shares 57
Omega Pharma Completes Public Offering Of Shares For US$237 Million 59
Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 60
Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 61
Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62
Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64
Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 65
Perrigo Completes Private Placement Of Notes Due 2023 For US$800 Million 67
Perrigo Completes Private Placement Of Notes Due 2043 For US$400 Million 67
Perrigo Completes Private Placement Of Notes Due 2018 For US$600 Million 68
Perrigo Completes Private Placement Of Notes Due 2016 For US$500 Million 69
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 70
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 71
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 72
Perrigo Completes Private Placement Of Notes Due 2023 For US$175 Million 73
Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For US$75 Million 74
Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For US$100 Million 74
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 75
Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 76
IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 77
Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 78
Watson Pharma Acquires Generic Pharma Products From Perrigo 79
Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 80
Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 81
Perrigo Acquires Omega Pharma for USD4.76 Billion 82
Ind-Swift Lab May Sell Stake in Company 83
Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 84
Perrigo To Acquire 7% Stake In Transition Therapeutics For US$15 Million 85
Perrigo Completes Acquisition Of Elan For US$8.6 Billion 86
Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For US$284 Million 88
Omega Pharma Acquires Naturoteek 90
Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For US$45 Million 90
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 91
Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For US$36 Million 92
Perrigo Completes Acquisition Of Paddock Labs 93
Perrigo Company Plc, Key Competitors 96
Perrigo Company Plc, Key Employees 97
Perrigo Company Plc, Subsidiaries 98List of Figures
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13
